What is a stock summary page? Click here for an overview.
Business Description
Relmada Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75955J2042
Compare
Compare
Traded in other countries / regions
RLMD.USA4E2.Germany Index Membership
Russell 3000Russell 2000 IPO Date
2014-03-03Description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.78 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27 | |||||
| 3-Year EPS without NRI Growth Rate | 27.8 | |||||
| 3-Year FCF Growth Rate | 31 | |||||
| 3-Year Book Growth Rate | -46.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.42 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.88 | |||||
| 9-Day RSI | 41.55 | |||||
| 14-Day RSI | 41.59 | |||||
| 3-1 Month Momentum % | -44.08 | |||||
| 6-1 Month Momentum % | -92.45 | |||||
| 12-1 Month Momentum % | -94.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.45 | |||||
| Quick Ratio | 4.45 | |||||
| Cash Ratio | 4.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -2.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -132.4 | |||||
| ROA % | -112.8 | |||||
| ROIC % | -5666.85 | |||||
| 3-Year ROIIC % | -8481.14 | |||||
| ROCE % | -138.87 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.23 | |||||
| Price-to-Tangible-Book | 0.23 | |||||
| EV-to-EBIT | 0.43 | |||||
| EV-to-EBITDA | 0.43 | |||||
| EV-to-Forward-Revenue | 0.53 | |||||
| EV-to-FCF | 0.69 | |||||
| Price-to-Net-Current-Asset-Value | 0.23 | |||||
| Price-to-Net-Cash | 0.24 | |||||
| Earnings Yield (Greenblatt) % | 232.56 | |||||
| FCF Yield % | -572.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RLMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relmada Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.65 | ||
| Beta | -0.13 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -0.63 | ||
| Volatility % | 96.49 | ||
| 14-Day RSI | 41.59 | ||
| 14-Day ATR ($) | 0.029569 | ||
| 20-Day SMA ($) | 0.28923 | ||
| 12-1 Month Momentum % | -94.39 | ||
| 52-Week Range ($) | 0.2404 - 5.09 | ||
| Shares Outstanding (Mil) | 33.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relmada Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relmada Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Relmada Therapeutics Inc Frequently Asked Questions
What is Relmada Therapeutics Inc(RLMD)'s stock price today?
The current price of RLMD is $0.27. The 52 week high of RLMD is $5.09 and 52 week low is $0.24.
When is next earnings date of Relmada Therapeutics Inc(RLMD)?
The next earnings date of Relmada Therapeutics Inc(RLMD) is 2025-05-08 Est..
Does Relmada Therapeutics Inc(RLMD) pay dividends? If so, how much?
Relmada Therapeutics Inc(RLMD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers